Leading the Way in Life Science Technologies

GEN Exclusives

More »


More »
September 15, 2009 (Vol. 29, No. 16)

Parvovirus B19 VLP Vaccine Manufacturing

Meridian Developed Production Process for Technology Licensed from NHLBI

  • Conclusions

    Multiple groups are at risk of potentially life-threatening complications due to human parvovirus B19 infection. Based on the infectious nature of HPVB19 infection in children and the severe potential consequence of transplacental fetal infection, a two-pronged vaccination strategy to manage HPVB19 infections in these populations is recommended.

    First, incorporation of a HPVB19 vaccine into the early childhood vaccination schedule could reduce the overall incidence of this virus in the population. Second, a safe vaccine that can elicit protective neutralizing antibodies could be provided to women of childbearing age as prophylactic care to reduce the overall incidence of transplacental fetal infection.

Related content